Please provide your email address to receive an email when new articles are posted on . The FDA has approved a supplemental biologics license application to expand the use of lanadelumab-flyo for ...
Please provide your email address to receive an email when new articles are posted on . Lanadelumab prevented hereditary angioedema attacks among patients aged 2 to younger than 12 years with no ...
Hereditary angioedema (HAE) is a rare genetic disorder that causes swelling in different areas of the body for several days. Ways to care for a child with HAE include helping prevent and manage ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ...
Two new studies being presented at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Orlando shed light on how hereditary angioedema (HAE) – a rare, ...
New research highlights care challenges faced by children and adolescents with hereditary angioedema
ORLANDO (Nov. 6, 2025) – Two new studies being presented at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Orlando shed light on how hereditary ...
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference ...
Two new studies presented at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Orlando shed light on how hereditary angioedema (HAE)—a rare, potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results